Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Apellis Pharmaceuticals / Equity Bottom-Up

<ul><li>Apellis Pharmaceuticals, a biopharmaceutical company, recently reported its earnings for the second quarter of 2024, presenting the progress and results for the period.</li><li>The management, specifically Chief Executive Officer Dr. Cedric Francois discussed the company's position with its products SYFOVRE and EMPAVELI, emphasizing SYFOVRE's leading market position in the treatment of geographic atrophy (GA), despite facing competitive pressures.</li><li>The company expressed optimism about SYFOVRE's robust performance in the market.</li></ul>

Apellis Pharmaceuticals, a biopharmaceutical company, recently reported its earnings for the second quarter of 2024, presenting the progress and results for the period.The management, specifically Chief Executive Officer Dr. Cedric Francois discussed the company's position with its products SYFOVRE and EMPAVELI, emphasizing SYFOVRE's leading market position in the treatment of geographic atrophy (GA), despite facing competitive pressures.The company expressed optimism about SYFOVRE's robust performance in the market.

Apellis Pharmaceuticals Inc.: Market Leadership & Differentiation of SYFOVRE Driving Our Bullishness! - Major Drivers

<ul><li>Apellis Pharmaceuticals experienced a strong start to the first quarter of 2024, showing significant growth particularly through its product SYFOVRE, which demonstrated impressive market uptake and robust sales growth.</li><li>SYFOVRE generated $137 million in net sales for the quarter, marking a 20% increase from the previous quarter.</li><li>This increase predominantly stemmed from accelerated demand as the product solidified its position in the market.</li></ul>

Apellis Pharmaceuticals experienced a strong start to the first quarter of 2024, showing significant growth particularly through its product SYFOVRE, which demonstrated impressive market uptake and robust sales growth.SYFOVRE generated $137 million in net sales for the quarter, marking a 20% increase from the previous quarter.This increase predominantly stemmed from accelerated demand as the product solidified its position in the market.

Apellis Pharmaceuticals Inc.: Strategic Marketing and Direct-to-Consumer (DTC) Campaigns Changing The Game! - Major Drivers

<ul><li>Apellis Pharmaceuticals delivered decent financial results for the fourth quarter and full year of 2023.</li><li>The company ended the year in a solid position, with two commercially successful products: SYFOVRE and EMPAVELI, both of which are playing central roles in improving patients’ lives.</li><li>In 2023, multiple positive data readouts and high compliance rates for EMPAVELI were achieved, positioning the company well for continued success in 2024.</li></ul>

Apellis Pharmaceuticals delivered decent financial results for the fourth quarter and full year of 2023.The company ended the year in a solid position, with two commercially successful products: SYFOVRE and EMPAVELI, both of which are playing central roles in improving patients’ lives.In 2023, multiple positive data readouts and high compliance rates for EMPAVELI were achieved, positioning the company well for continued success in 2024.

Apellis Pharmaceuticals Inc.: Initiation Of Coverage -  A Dominant Force In PNH & Nephrology Market - Major Drivers

Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Thematic (Sector/Industry)

<ul><li>We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.</li><li>Last week, ALDX completed the additional study needed to resubmit dry eye NDA.</li><li>Kidney disease drugs continue to benefit from regulatory tailwinds, as NVS gained IgAN approval and APLS succeeded in a pivotal biomarker study in C3G/IC- MPGN.</li></ul>

We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.Last week, ALDX completed the additional study needed to resubmit dry eye NDA.Kidney disease drugs continue to benefit from regulatory tailwinds, as NVS gained IgAN approval and APLS succeeded in a pivotal biomarker study in C3G/IC- MPGN.

Biopharma Week in Review - August 12, 2024

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/astellas-pharma-inc" target="_blank" data-smartkarma-citation="entities:6091:1" rel="noopener">Astellas Pharma (4503 JP)</a> reported Q1FY24 results, with revenue beating and operating and net profit missing consensus. Revenue declined 2%, while operating and net profit increased 17% and 13%, respectively.</li>
<li>Astellas has reiterated FY24 revenue guidance of ¥1,520B, while reduced operating profit guidance by ¥29B to ¥259B (+95% YoY) and net profit guidance by ¥23B to ¥204B (+106% YoY).</li>
<li>On August 4, Iveric Bio has received FDA approval for Izervay for the treatment of geographic atrophy secondary to age-related macular degeneration, which impacts approximately 1.5M people in the U.S.  </li>
</ul>



Astellas Pharma (4503 JP) reported Q1FY24 results, with revenue beating and operating and net profit missing consensus. Revenue declined 2%, while operating and net profit increased 17% and 13%, respectively.
Astellas has reiterated FY24 revenue guidance of ¥1,520B, while reduced operating profit guidance by ¥29B to ¥259B (+95% YoY) and net profit guidance by ¥23B to ¥204B (+106% YoY).
On August 4, Iveric Bio has received FDA approval for Izervay for the treatment of geographic atrophy secondary to age-related macular degeneration, which impacts approximately 1.5M people in the U.S.  


Astellas Pharma (4503 JP): Mixed Q1 Result; FY24 Profit Guidance Cut; New Drug Approval

United States

Apellis Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Apellis Pharmaceuticals serves clients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Apellis Pharmaceuticals (APLS US)

Apellis Pharmaceuticals Inc.: Market Leadership & Differentiation of SYFOVRE Driving Our Bullishness! - Major Drivers

Apellis Pharmaceuticals, a biopharmaceutical company, recently reported its earnings for the second quarter of 2024, presenting the progress and...

Baptista Research

Apellis Pharmaceuticals Inc.: Strategic Marketing and Direct-to-Consumer (DTC) Campaigns Changing The Game! - Major Drivers

Apellis Pharmaceuticals experienced a strong start to the first quarter of 2024, showing significant growth particularly through its product...

Baptista Research

Apellis Pharmaceuticals Inc.: Initiation Of Coverage - A Dominant Force In PNH & Nephrology Market - Major Drivers

Apellis Pharmaceuticals delivered decent financial results for the fourth quarter and full year of 2023. The company ended the year in a solid...

Baptista Research

Biopharma Week in Review - August 12, 2024

We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&A.

Water Tower Research

Astellas Pharma (4503 JP): Mixed Q1 Result; FY24 Profit Guidance Cut; New Drug Approval

In Q1 revenue declined 2%, while operating and net profit increased 17% and 13%, respectively. Astellas reduced FY24 operating profit guidance by...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)